Cellceutix Reports Results for Quarter Ended March 31, 2015; Enrollment for Oral Mucositis Studies to Begin This Month
Marketwired - Wed May 13, 6:01AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Cellceutix Selects Independent Directors and Committee Members
Marketwired - Mon Apr 27, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
CellCeutix: Comparing Brilacidin With SoC Daptomycin
Kanak Kanti De - at Seeking Alpha - Tue Apr 21, 12:37PM CDT
Cellceutix Provides Corporate Update
Marketwired - Tue Apr 21, 9:06AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Cellceutix PIND Meeting Scheduled With FDA for Hidradenitis Suppurativa
Marketwired - Mon Apr 13, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Cellceutix Corporation - Product Pipeline Review - 2015
M2 - Thu Apr 09, 1:48AM CDT
Summary
Cellceutix closes $30M stock purchase agreement
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 7:59AM CDT
Cellceutix Enters Into a $30 Million Common Stock Purchase Agreement
Marketwired - Wed Apr 01, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Tenth Cohort Completed in Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin, No Adverse Events Reported
Marketwired - Tue Mar 24, 7:29AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Cellceutix Advancing Treatment for Hidradenitis Suppurativa, Pre-IND Meeting Request to Food and Drug Administration
Marketwired - Mon Mar 16, 7:33AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Ulcerative Colitis Therapeutics Pipeline Review 2015 - 66 Companies & 99 Drug Profiles
M2 - Tue Mar 03, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwqzpf/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ajinomoto Pharmaceuticals Co., Ltd. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Am-Pharma B.V. - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Athersys, Inc. - Atlantic Healthcare plc - Avaxia Biologics, Inc. - Biocon Limited - BioLineRx, Ltd. - Bristol-Myers Squibb Company - Celgene Corporation - Cellceutix Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Cosmo Pharmaceuticals S.p.A - Dr. Falk Pharma GmbH - Drais Pharmaceuticals, Inc. - Effimune SAS - Emergent BioSolutions Inc. - Enceladus Pharmaceuticals BV - Epirus Biopharmaceuticals, Inc. - Euroscreen S.A. - Farmacija d.o.o. Tuzla - Flexion Therapeutics, Inc. - Galapagos NV - Genentech, Inc. For more information visit http://www.researchandmarkets.com/research/kwqzpf/ulcerative
FLXN: 18.45 (-0.20), EBS: 30.72 (+0.47), AMGN: 162.36 (+0.38), BMY: 67.64 (+0.19), AZN: 69.29 (-0.81), CCXI: 7.21 (-0.09), ATHX: 1.27 (-0.01), CELGZ: 2.60 (-0.10)
Cellceutix to Expand Its Skin Product Pipeline
Marketwired - Mon Mar 02, 8:32AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 224.63 (+1.81), ACT: 296.60 (-0.86), MDT: 76.42 (+0.16), XON: 40.08 (-0.90), CTIC: 1.80 (+0.04), PFNX: 13.70 (+0.60), JNJ: 102.30 (+0.47), ANTM: 161.37 (+1.37), NVAX: 8.54 (-0.09), SHPG: 254.45 (+3.99), ABBV: 65.99 (+0.02), TBPH: 14.69 (-0.24), SNY: 50.52 (-0.27), ALQA: 4.48 (-0.27), REGN: 489.01 (-2.42), ONCY: 0.71 (unch), PFE: 33.99 (+0.05), SLXP: 172.96 (+0.15), EPRS: 5.61 (-0.14), AMGN: 162.36 (+0.38), NKTR: 11.13 (+0.20), ZTS: 46.49 (+0.21), GILD: 109.30 (+0.56), ACHN: 9.57 (+0.05), GERN: 3.89 (-0.02)
IHUB Most Posted And Most Read Stocks Do Not Perform Well
Anthony Cataldo - at Seeking Alpha - Wed Feb 11, 8:43AM CST
PPHM: 1.37 (+0.05)
An Interview With Cellceutix CEO Leo Ehrlich
KarinCA - at Seeking Alpha - Mon Feb 09, 9:31AM CST
MRK: 60.23 (+0.45)
Cellceutix: Why An Uplisting Is Not Possible Right Now
Bleecker Street Research - at Seeking Alpha - Fri Feb 06, 1:26PM CST
$CTIX - Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon
KarinCA - at Seeking Alpha - Thu Jan 29, 3:13PM CST
JNJ: 102.30 (+0.47), CBSTZ: 0.06 (unch), ACT: 296.60 (-0.86), PFE: 33.99 (+0.05), MRK: 60.23 (+0.45), AMGN: 162.36 (+0.38), LLY: 72.90 (-0.16), ABBV: 65.99 (+0.02), NVS: 103.75 (-0.15)
Cellceutix Plans Clinical Trial in Patients With Ulcerative Proctitis
Marketwired - Mon Jan 26, 6:00AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
Cellceutix: A December To Remember May Turn Into A 2015 To Forget For CTIX
Bleecker Street Research - at Seeking Alpha - Fri Jan 23, 9:30AM CST
Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 6:36AM CST
The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipel...eport.html .
TEVA: 60.23 (-0.99), ITCI: 22.91 (-0.27), BCLI: 3.66 (-0.04), OMER: 20.88 (-0.01), NVS: 103.75 (-0.15)